BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vlad AM, Budiu RA, Lenzner DE, Wang Y, Thaller JA, Colonello K, Crowley-Nowick PA, Kelley JL, Price FV, Edwards RP. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother 2010;59:293-301. [PMID: 19690855 DOI: 10.1007/s00262-009-0750-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Grisaru-Tal S, Itan M, Klion AD, Munitz A. A new dawn for eosinophils in the tumour microenvironment. Nat Rev Cancer 2020;20:594-607. [PMID: 32678342 DOI: 10.1038/s41568-020-0283-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
2 Uppendahl LD, Dahl CM, Miller JS, Felices M, Geller MA. Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review. Front Immunol 2017;8:1825. [PMID: 29354116 DOI: 10.3389/fimmu.2017.01825] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
3 Drerup JM, Liu Y, Padron AS, Murthy K, Hurez V, Zhang B, Curiel TJ. Immunotherapy for ovarian cancer. Curr Treat Options Oncol 2015;16:317. [PMID: 25648541 DOI: 10.1007/s11864-014-0317-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
4 Bronte G, Cicero G, Sortino G, Pernice G, Catarella MT, D'alia P, Cusenza S, Lo Dico S, Bronte E, Sprini D, Midiri M, Firenze A, Fiorentino E, Bazan V, Rolfo C, Russo A. Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy? Expert Opinion on Biological Therapy 2013;14:103-14. [DOI: 10.1517/14712598.2014.859671] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
5 Le Saux O, Ray-coquard I, Labidi-galy SI. Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. Seminars in Cancer Biology 2020. [DOI: 10.1016/j.semcancer.2020.08.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
6 Coukos G, Tanyi J, Kandalaft LE. Opportunities in immunotherapy of ovarian cancer. Ann Oncol 2016;27 Suppl 1:i11-5. [PMID: 27141063 DOI: 10.1093/annonc/mdw084] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
7 Hansen JM, Coleman RL, Sood AK. Targeting the tumour microenvironment in ovarian cancer. Eur J Cancer. 2016;56:131-143. [PMID: 26849037 DOI: 10.1016/j.ejca.2015.12.016] [Cited by in Crossref: 58] [Cited by in F6Publishing: 63] [Article Influence: 9.7] [Reference Citation Analysis]
8 Demircan NC, Boussios S, Tasci T, Öztürk MA. Current and future immunotherapy approaches in ovarian cancer. Ann Transl Med 2020;8:1714. [PMID: 33490226 DOI: 10.21037/atm-20-4499] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
9 Mantia-Smaldone GM, Corr B, Chu CS. Immunotherapy in ovarian cancer. Hum Vaccin Immunother 2012;8:1179-91. [PMID: 22906947 DOI: 10.4161/hv.20738] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
10 Mantia-Smaldone GM, Edwards RP, Vlad AM. Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies. Cancer Manag Res 2011;3:25-38. [PMID: 21734812 DOI: 10.2147/CMR.S8759] [Cited by in Crossref: 5] [Cited by in F6Publishing: 31] [Article Influence: 0.4] [Reference Citation Analysis]
11 Hagemann AR, Hagemann IS, Cadungog M, Hwang WT, Patel P, Lal P, Hammond R, Gimotty PA, Chu CS, Rubin SC, Birrer MJ, Powell DJ Jr, Feldman MD, Coukos G. Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma. Cancer Biol Ther 2011;12:367-77. [PMID: 21785280 DOI: 10.4161/cbt.12.4.16908] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
12 Thaker PH, Borys N, Fewell J, Anwer K. GEN-1 immunotherapy for the treatment of ovarian cancer. Future Oncol 2019;15:421-38. [PMID: 30325199 DOI: 10.2217/fon-2018-0423] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
13 Kandalaft LE, Chiang CL, Tanyi J, Motz G, Balint K, Mick R, Coukos G. A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. J Transl Med 2013;11:149. [PMID: 23777306 DOI: 10.1186/1479-5876-11-149] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
14 Santos JM, Heiniö C, Cervera-Carrascon V, Quixabeira DCA, Siurala M, Havunen R, Butzow R, Zafar S, de Gruijl T, Lassus H, Kanerva A, Hemminki A. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity. J Immunother Cancer 2020;8:e000188. [PMID: 31940588 DOI: 10.1136/jitc-2019-000188] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
15 Turner TB, Buchsbaum DJ, Straughn JM Jr, Randall TD, Arend RC. Ovarian cancer and the immune system - The role of targeted therapies. Gynecol Oncol 2016;142:349-56. [PMID: 27174875 DOI: 10.1016/j.ygyno.2016.05.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
16 Krishnan V, Berek JS, Dorigo O. Immunotherapy in ovarian cancer. Current Problems in Cancer 2017;41:48-63. [DOI: 10.1016/j.currproblcancer.2016.11.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
17 Brueseke TJ, Tewari KS. Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma. Clin Pharmacol 2013;5:13-9. [PMID: 23723721 DOI: 10.2147/CPAA.S40401] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
18 Oh HK, Sin JI, Choi J, Park SH, Lee TS, Choi YS. Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration. J Gynecol Oncol 2012;23:274-81. [PMID: 23094131 DOI: 10.3802/jgo.2012.23.4.274] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
19 Tran E, Nielsen JS, Wick DA, Ng AV, Johnson LD, Nesslinger NJ, McMurtrie E, Webb JR, Nelson BH. Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines. PLoS One 2010;5:e15625. [PMID: 21203522 DOI: 10.1371/journal.pone.0015625] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
20 Kandalaft LE, Coukos G. The Microenvironment of Ovarian Cancer: Lessons on Immune Mediated Tumor Rejection or Tolerance. In: Marincola FM, Wang E, editors. Immunologic Signatures of Rejection. New York: Springer; 2011. pp. 211-28. [DOI: 10.1007/978-1-4419-7219-4_14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
21 Schuster H, Peper JK, Bösmüller HC, Röhle K, Backert L, Bilich T, Ney B, Löffler MW, Kowalewski DJ, Trautwein N, Rabsteyn A, Engler T, Braun S, Haen SP, Walz JS, Schmid-Horch B, Brucker SY, Wallwiener D, Kohlbacher O, Fend F, Rammensee HG, Stevanović S, Staebler A, Wagner P. The immunopeptidomic landscape of ovarian carcinomas. Proc Natl Acad Sci U S A 2017;114:E9942-51. [PMID: 29093164 DOI: 10.1073/pnas.1707658114] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 16.6] [Reference Citation Analysis]
22 You Q, Yao Y, Zhang Y, Fu S, Du M, Zhang G. Effect of targeted ovarian cancer therapy using amniotic fluid mesenchymal stem cells transfected with enhanced green fluorescent protein-human interleukin-2 in vivo. Mol Med Rep 2015;12:4859-66. [PMID: 26179662 DOI: 10.3892/mmr.2015.4076] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
23 Duwa R, Jeong J, Yook S. Immunotherapeutic strategies for the treatment of ovarian cancer: current status and future direction. Journal of Industrial and Engineering Chemistry 2021;94:62-77. [DOI: 10.1016/j.jiec.2020.11.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
24 Nolen BM, Lokshin AE. Targeting CCL11 in the treatment of ovarian cancer. Expert Opin Ther Targets 2010;14:157-67. [PMID: 20055715 DOI: 10.1517/14728220903512983] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
25 Budiu RA, Mantia-Smaldone G, Elishaev E, Chu T, Thaller J, McCabe K, Lenzner D, Edwards RP, Vlad AM. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Cancer Immunol Immunother 2011;60:975-84. [PMID: 21461842 DOI: 10.1007/s00262-011-1010-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
26 Minor DR, Moores SP, Chan JK. Prolonged survival after intraperitoneal interleukin-2 immunotherapy for recurrent ovarian cancer. Gynecol Oncol Rep 2017;22:43-4. [PMID: 29034306 DOI: 10.1016/j.gore.2017.09.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
27 Ingersoll SB, Ahmad S, McGann HC, Banks RK, Stavitzski NM, Srivastava M, Ali G, Finkler NJ, Edwards JR, Holloway RW. Cellular therapy in combination with cytokines improves survival in a xenograft mouse model of ovarian cancer. Mol Cell Biochem 2015;407:281-7. [PMID: 26048718 DOI: 10.1007/s11010-015-2475-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
28 Grabosch S, Tseng G, Edwards RP, Lankes HA, Moore K, Odunsi K, Vlad A, Ma T, Strange M, Brozick J, Lugade A, Omilian A, Bshara W, Stuckey AR, Walker JL, Birrer M. Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 2017;146:137-45. [PMID: 28483269 DOI: 10.1016/j.ygyno.2017.04.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
29 Santoiemma PP, Powell DJ Jr. Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther. 2015;16:807-820. [PMID: 25894333 DOI: 10.1080/15384047.2015.1040960] [Cited by in Crossref: 133] [Cited by in F6Publishing: 135] [Article Influence: 19.0] [Reference Citation Analysis]
30 Puskas J, Skrombolas D, Sedlacek A, Lord E, Sullivan M, Frelinger J. Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases. Immunology 2011;133:206-20. [PMID: 21426339 DOI: 10.1111/j.1365-2567.2011.03428.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
31 Mony JT, Zhang L, Ma T, Grabosch S, Tirodkar TS, Brozick J, Tseng G, Elishaev E, Edwards RP, Huang X, Vlad AM. Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model. Cancer Immunol Immunother 2015;64:1095-108. [PMID: 25998800 DOI: 10.1007/s00262-015-1712-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
32 Hutchinson L. Robust responses to intraperitoneal IL-2 in ovarian cancer. Nat Rev Clin Oncol 2010;7:122-122. [DOI: 10.1038/nrclinonc.2010.4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
33 Kandalaft LE, Powell DJ, Singh N, Coukos G. Immunotherapy for ovarian cancer: what’s next? J Clin Oncol. 2011;29:925-933. [PMID: 21079136 DOI: 10.1200/jco.2009.27.2369] [Cited by in Crossref: 86] [Cited by in F6Publishing: 54] [Article Influence: 7.2] [Reference Citation Analysis]
34 Kawano K, Tsuda N, Matsueda S, Sasada T, Watanabe N, Ushijima K, Yamaguchi T, Yokomine M, Itoh K, Yamada A, Kamura T. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. Immunopharmacol Immunotoxicol 2014;36:224-36. [PMID: 24773550 DOI: 10.3109/08923973.2014.913617] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
35 Silveira HS, Lupi LA, Romagnoli GG, Kaneno R, da Silva Nunes I, Fávaro WJ, de Almeida Chuffa LG. P-MAPA activates TLR2 and TLR4 signaling while its combination with IL-12 stimulates CD4+ and CD8+ effector T cells in ovarian cancer. Life Sciences 2020;254:117786. [DOI: 10.1016/j.lfs.2020.117786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
36 Kandalaft LE, Motz GT, Duraiswamy J, Coukos G. Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. Cancer Metastasis Rev 2011;30:141-51. [PMID: 21298574 DOI: 10.1007/s10555-011-9289-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]